Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1277-1283

  Kolonias, Despina ^a   Podona, Tchao ^a   Savaraj, Niramol ^b   Gate, Laurent ^c   Cossum, Paul ^d   Lampidis, Theodore J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d Antigenics Inc   (United States)

Author keywords

Adriamycin; Annamycin; Cardiac cell lines; MDR tumor cells

Indexed keywords

ANNAMYCIN; ANTINEOPLASTIC AGENT; DOXORUBICIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARDIOTOXICITY; CELL GROWTH; CONTROLLED STUDY; CYTOSOL; DRUG ACCUMULATION; DRUG EFFICACY; GROWTH INHIBITION; HEART MUSCLE CELL; LEUKEMIA CELL; MOUSE; MULTIDRUG RESISTANCE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HEART; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED;

EID: 0033041082     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lampidis TJ, Henderson IC, Israel M and Canellos, GP: Structural and functional effects of Adriamycin on cardiac cells in vitro. Cancer Res 40: 3901-3909, 1980.
2. Lampidis TJ, Johnson LV and Israel M: Effects of Adriamycin on rat heart cells in culture: increased accumulation and nucleoli fragmentation in cardiac muscle vs non-muscle cells. J Mol Cell Cardiol 13: 913-924, 1981.
3. Lenaz I and Page JA: Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat. Rev 3: 111-120, 1976.
4. Tapiero H, Munck JN, Bennoun M, Fourcade A, and Lampidis TJ: Cross-resistance to Rhodamine 123 in adriamycin and daunomycin resistant Friend leukemia cell variants. Cancer Res 44: 5544-5549, 1984.
5. Lampidis TJ, Savaraj N, Valet GK, Trevorrow K, Fourcade A, and Tapiero H: Relationship of chemical charge of anti-cancer agents to increased accumulation and cytotoxicity in cardiac and tumor cells: Relevance to multidrug resistance. J Cell Pharm 1: 16-22, 1989.
6. Lampidis TJ, Kolonias D, Podona T, Isreal M, Safa A, Lothstein L, Savaraj N, Tapiero H, and Priebe W: CircDvention of P-gp mdr as a function of anthracyclines lipophilicity and charge. Biochemistry 36: 2679-2685, 1997.
7. Israel M, Seshadri R, Koseki Y, Sweatman TW and Idriss J M: Amelioration of Adriamycin toxicity through modification of drug-DNA binding properties. Cancer Treat Rev 14: 163-167, 1987.
8. Priebe W: Mechanism of action-governed design of anthracycline antibiotics: A "Turn-off/Turn-on" approach. Current Drug Design 1: 73-96, 1995.
9. Perez-Soler R, Ling YH, Zou Y and Priebe W: Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells. Cancer Chemother Pharmacol 34: 109-118, 1994.
10. Zou Y, Ling YH, Van NT, Priebe W and Perez-Soler R: Antitumour activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res 54: 1479-1484, 1994.
11. Consoli U, Priebe W, Ling YH, Mahadevia R, Griffin M, Zhao S, Perez-Soler R and Andreeff M: The novel anthracycline Annamycin is not affected by p-glycoprotein-related multidrug resistance: Comparison with Idarubicin and Doxorubicin in HL-60 leukemia cell lines. Blood 88 (2): 633-644, 1996.
12. Zou Y, Priebe W, Stephens C and Perez-Soler R: Preclinical toxicity of liposome incorporated Annamycin: Selective bone marrow toxicity with lack of cardiotoxicity. Clin Cancer Res 1: 1369-1374, 1995.
13. Mark GE and Strasser FF: Pacemaker activity and mitosis in cultures of newborn rat heart ventricle cells. Exp Cell Res 44: 217-233, 1967.
14. Lampidis TJ, Trevorrow KW, and Rubin RW: Effects of colchicine on cardiac cell function indicate a possible role for membrane surface tubulin. Exptl Cell Res 164: 463-470, 1986.
15. Savaraj N, Lampidis TJ, Zhao ZY, Wu CJ, Teeter LD and Kuo MT: Multidrug resistant cells selected with different drugs is associated with overproduction of different glycoproteins. Cancer Invest 12(2): 138-144, 1994.
16. Lampidis TJ, Weiss M, Hassan J and Chen LB: Selective killing of carcinoma cells in vitro by several different cationic lipophilic compounds: A cellular basis. Biomed. & Pharm. 39: 220-226, 1985.
17. Fourcade A, Farhi JJ, Bennoun M and Tapiero H: Uptake, efflux and hydrolysis of Aclacinomycin A in Friend leukemia cells. Cancer Res 42: 1950-1954, 1982.
18. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum S, Silber R, and Potmesil M: DNA topoisomerase II-mediated interaction of Doxorubicin and Daunorubicin congeners with DNA. Cancer Res 49: 5969-5978, 1989.